{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T14:11:45Z","timestamp":1771078305876,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41401-025-01661-0","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:01:05Z","timestamp":1759312865000},"page":"383-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase III clinical trial of monthly minodronate in the treatment of Chinese postmenopausal women with osteoporosis"],"prefix":"10.1038","volume":"47","author":[{"given":"Hao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-nan","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-feng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-fu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-hua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-zhen","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-long","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu-jun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-pan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-qing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-jiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-luo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-xi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan-feng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-jun","family":"Bing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-jie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-ping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-min","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bu-jun","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"1661_CR1","doi-asserted-by":"publisher","first-page":"e2121106","DOI":"10.1001\/jamanetworkopen.2021.21106","volume":"4","author":"L Wang","year":"2021","unstructured":"Wang L, Yu W, Yin X, Cui L, Tang S, Jiang N, et al. Prevalence of osteoporosis and fracture in China: The China osteoporosis prevalence study. JAMA Netw Open. 2021;4:e2121106.","journal-title":"JAMA Netw Open"},{"key":"1661_CR2","doi-asserted-by":"publisher","first-page":"e1003180","DOI":"10.1371\/journal.pmed.1003180","volume":"17","author":"C Zhang","year":"2020","unstructured":"Zhang C, Feng J, Wang S, Gao P, Xu L, Zhu J, et al. Incidence of and trends in hip fracture among adults in urban China: a nationwide retrospective cohort study. PLoS Med. 2020;17:e1003180.","journal-title":"PLoS Med"},{"key":"1661_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41401-022-00954-y","volume":"44","author":"H Zhang","year":"2023","unstructured":"Zhang H, Gu JM, Chao AJ, Cheng Q, Teng DH, Yu JM, et al. A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk. Acta Pharmacol Sin. 2023;44:446\u201353.","journal-title":"Acta Pharmacol Sin"},{"key":"1661_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/aps.2015.30","volume":"36","author":"JM Gu","year":"2015","unstructured":"Gu JM, Wang L, Lin H, Chen DC, Tang H, Jin XL, et al. The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. Acta Pharmacol Sin. 2015;36:841\u20136.","journal-title":"Acta Pharmacol Sin"},{"key":"1661_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/bcr414","volume":"4","author":"H Fleisch","year":"2002","unstructured":"Fleisch H. Development of bisphosphonates. Breast Cancer Res. 2002;4:30\u20134.","journal-title":"Breast Cancer Res"},{"key":"1661_CR6","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00198-012-2108-5","volume":"24","author":"D Weycker","year":"2013","unstructured":"Weycker D, Lamerato L, Schooley S, Macarios D, Siu Woodworth T, Yurgin N, et al. Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice. Osteoporos Int. 2013;24:1483\u20139.","journal-title":"Osteoporos Int"},{"key":"1661_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-018-0530-9","volume":"13","author":"M Belhassen","year":"2018","unstructured":"Belhassen M, Cortet B, Confavreux CB, Lamezec L, Ginoux M, Van Ganse E. Impact of bisphosphonate compliance on the risk of osteoporotic fracture in France. Arch Osteoporos. 2018;13:113.","journal-title":"Arch Osteoporos"},{"key":"1661_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","volume":"115","author":"AN Tosteson","year":"2003","unstructured":"Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115:209\u201316.","journal-title":"Am J Med"},{"key":"1661_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","volume":"122","author":"ES Siris","year":"2009","unstructured":"Siris ES, Selby PL, Saag KG, Borgstr\u00f6m F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122:S3\u201313.","journal-title":"Am J Med"},{"key":"1661_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","volume":"296","author":"JE Dunford","year":"2001","unstructured":"Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235\u201342.","journal-title":"J Pharmacol Exp Ther"},{"key":"1661_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3109\/s10165-007-0566-y","volume":"17","author":"S Tanishima","year":"2007","unstructured":"Tanishima S, Kishimoto Y, Fukata S, Mizumura H, Hagino H, Teshima R. Minodronic acid influences receptor activator of nuclear factor kappaB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis. Mod Rheumatol. 2007;17:198\u2013205.","journal-title":"Mod Rheumatol"},{"key":"1661_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pr. 2020;26:1\u201346.","journal-title":"Endocr Pr"},{"key":"1661_CR13","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00198-008-0816-7","volume":"20","author":"T Matsumoto","year":"2009","unstructured":"Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int. 2009;20:1429\u201337.","journal-title":"Osteoporos Int"},{"key":"1661_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00774-011-0332-2","volume":"30","author":"H Hagino","year":"2012","unstructured":"Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, et al. Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Min Metab. 2012;30:439\u201346.","journal-title":"J Bone Min Metab"},{"key":"1661_CR15","first-page":"346","volume":"57","author":"C Peng","year":"2022","unstructured":"Peng C, Tian R, Li L, Zhu YK, Li SY, Ye SD, et al. A randomized double-blinded placebo-controlled clinical trial of minodronate tablet in postmenopausal Chinese women with osteoporosis. Zhonghua Fu Chan Ke Za Zhi. 2022;57:346\u201351.","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"1661_CR16","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00198-011-1782-z","volume":"23","author":"R Okazaki","year":"2012","unstructured":"Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, et al. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int. 2012;23:1737\u201345.","journal-title":"Osteoporos Int"},{"key":"1661_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jocd.2016.03.002","volume":"19","author":"T Ohishi","year":"2016","unstructured":"Ohishi T, Fujita T, Suzuki D, Nishida T, Okabayashi R, Yamamoto K, et al. Initiation of monthly minodronate therapy at an early stage after hip fracture. J Clin Densitom. 2016;19:352\u20138.","journal-title":"J Clin Densitom"},{"key":"1661_CR18","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.bone.2009.02.016","volume":"44","author":"H Hagino","year":"2009","unstructured":"Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, et al. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone. 2009;44:1078\u201384.","journal-title":"Bone"},{"key":"1661_CR19","first-page":"232","volume":"42","author":"T Ohishi","year":"2017","unstructured":"Ohishi T, Fujita T, Suzuki D, Nishida T, Yamamoto K, Okabayashi R, et al. Changes of bone mineral density and serum pentosidine during a 27-month follow-up of monthly minodronate in osteoporotic patients. Endocr Res. 2017;42:232\u201340.","journal-title":"Endocr Res"},{"key":"1661_CR20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00774-009-0138-7","volume":"28","author":"M Ito","year":"2010","unstructured":"Ito M, Sone T, Fukunaga M. Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis. J Bone Min Metab. 2010;28:334\u201341.","journal-title":"J Bone Min Metab"},{"key":"1661_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.afos.2016.07.002","volume":"2","author":"M Kamimura","year":"2016","unstructured":"Kamimura M, Nakamura Y, Ikegami S, Komatsu M, Uchiyama S, Kato H. Monthly minodronate inhibits bone resorption to a greater extent than does monthly risedronate. Osteoporos Sarcopenia. 2016;2:170\u201374.","journal-title":"Osteoporos Sarcopenia"},{"key":"1661_CR22","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00198-014-2756-8","volume":"25","author":"A Sakai","year":"2014","unstructured":"Sakai A, Ikeda S, Okimoto N, Matsumoto H, Teshima K, Okazaki Y, et al. Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study. Osteoporos Int. 2014;25:2245\u201353.","journal-title":"Osteoporos Int"},{"key":"1661_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s00223-023-01060-9","volume":"112","author":"H Ohta","year":"2023","unstructured":"Ohta H, Uemura Y, Sone T, Tanaka S, Soen S, Mori S, et al. Effect of bone resorption inhibitors on serum cholesterol level and fracture risk in osteoporosis: randomized comparative study between minodronic acid and raloxifene. Calcif Tissue Int. 2023;112:430\u201339.","journal-title":"Calcif Tissue Int"},{"key":"1661_CR24","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00774-019-00990-5","volume":"37","author":"A Taguchi","year":"2019","unstructured":"Taguchi A, Uemura Y, Imai T, Tanaka S, Ohta H, Nakamura T, et al. Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid. J Bone Min Metab. 2019;37:886\u201392.","journal-title":"J Bone Min Metab"},{"key":"1661_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jbspin.2007.07.011","volume":"75","author":"P Hadji","year":"2008","unstructured":"Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine. 2008;75:303\u201310.","journal-title":"Joint Bone Spine"},{"key":"1661_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10067-008-1039-1","volume":"28","author":"D Kastelan","year":"2009","unstructured":"Kastelan D, Lozo P, Stamenkovic D, Miskic B, Vlak T, Kolak Z, et al. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Clin Rheumatol. 2009;28:321\u20136.","journal-title":"Clin Rheumatol"},{"key":"1661_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00774-015-0653-7","volume":"34","author":"J Iwamoto","year":"2016","unstructured":"Iwamoto J, Okano H, Furuya T, Urano T, Hasegawa M, Hirabayashi H, et al. Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: minodroate alendronate\/risedronate trial in osteoporosis (MARTO). J Bone Min Metab. 2016;34:201\u20138.","journal-title":"J Bone Min Metab"},{"key":"1661_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-015-0231-6","volume":"10","author":"H Kishimoto","year":"2015","unstructured":"Kishimoto H, Maehara M. Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos. 2015;10:231.","journal-title":"Arch Osteoporos"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01661-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01661-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01661-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T14:06:46Z","timestamp":1768572406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01661-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1661"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01661-0","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JXZ, ZMZ and BJZ are employees of the study sponsor (Shandong New Time Pharmaceutical Co., Ltd, Linyi, China) at the time of study. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}